Theravance Biopharma/$TBPH
1D1W1MYTD1Y5YMAX
Capital at risk
About Theravance Biopharma
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
- Ticker
- $TBPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 90
- Headquarters
- South San Francisco, United States
- Website
- www.theravance.com
TBPH Metrics
BasicAdvanced
$884M
16.30
$1.05
0.25
-
Price and volume
Market cap
$884M
Beta
0.25
52-week high
$21.03
52-week low
$13.08
Average daily volume
476K
Financial strength
Current ratio
13.543
Quick ratio
13.263
Long term debt to equity
0.096
Total debt to equity
0.096
Interest coverage (TTM)
8.27%
Profitability
EBITDA (TTM)
11.102
Gross margin (TTM)
75.06%
Net profit margin (TTM)
51.58%
Operating margin (TTM)
9.16%
Effective tax rate (TTM)
8.67%
Revenue per employee (TTM)
$1,160,000
Management effectiveness
Return on assets (TTM)
1.33%
Return on equity (TTM)
20.91%
Valuation
Price to earnings (TTM)
16.296
Price to revenue (TTM)
8.34
Price to book
3.05
Price to tangible book (TTM)
3.05
Price to free cash flow (TTM)
16.19
Free cash flow yield (TTM)
6.18%
Free cash flow per share (TTM)
1.052
Growth
Revenue change (TTM)
35.11%
Earnings per share change (TTM)
308.45%
3-year revenue growth (CAGR)
26.72%
10-year revenue growth (CAGR)
10.49%
3-year earnings per share growth (CAGR)
-57.10%
10-year earnings per share growth (CAGR)
-14.04%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Analyst projections of the future price of Theravance Biopharma stock.
Bulls say / Bears say
The announced Zymeworks transaction provides shareholders with $17.00 per share in cash plus a CVR tied to 80% of future net proceeds from ampreloxetine monetization, creating a defined near-term value realization path. (Reuters)
YUPELRI collaboration revenue rose 11% year over year to $20.7 million in the second quarter of 2026, while operating expenses excluding restructuring and transaction costs fell 35% year over year, supporting improved cash generation. (Theravance Biopharma)
TBPH ended the second quarter with $388 million of cash and no debt, and reported high confidence in achieving the $100 million 2026 TRELEGY milestone, strengthening liquidity and potential shareholder value before the merger closes. (Theravance Biopharma)
The proposed Zymeworks acquisition is not yet closed: it remains subject to shareholder approval, antitrust clearance and other customary conditions, leaving TBPH exposed to deal-break risk and timing uncertainty. (SEC)
Ampreloxetine’s Phase 3 CYPRESS trial failed its primary endpoint, prompting the company to wind down the program; the related CVR is highly speculative, with no assurance that future monetization or payments will occur. (SEC)
TBPH remains reliant on YUPELRI and milestone income after the pipeline setback, while reporting a $5.9 million second-quarter 2026 net loss and a $10.8 million first-half net loss. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
TBPH News
AllArticlesVideos
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire1 month ago
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 months ago
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Benzinga3 months ago
Funds containing TBPH
AllUSDGBPEUR
Fund name | Fund size | $TBPH weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.